Anika Therapeutics (ANIK) vs Profound Medical (PROF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Anika Therapeutics (ANIK) has outperformed Profound Medical (PROF) over the past year, gaining 114.9% versus a loss of 12.1%. Over five years, ANIK leads with a -53.1% price change compared with -62.2% for PROF. Anika Therapeutics is the larger company by market cap ($261.4 million vs $207.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIK | PROF |
|---|---|---|
| Share price | $19.53 | $5.68 |
| Market cap | $261.37M | $207.55M |
| 1-day change | +2.14% | -6.58% |
| YTD return | +103.23% | -27.83% |
| 1-year return | +114.85% | -12.07% |
| 5-year return | -53.12% | -62.16% |
| Forward P/E | 20.56 | — |
| EPS (TTM) | $-0.23 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.88 | $8.95 |
| 52-week low | $8.67 | $4.80 |
| Distance from 52-week high | -14.64% | -36.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +17.77% | +96.13% |
| Average volume | 98.17K | 121.06K |
| Shares outstanding | 13.38M | 36.54M |
| Employees | 235 | 162 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIK has outperformed PROF by 126.9 percentage points over the past year.
About Anika Therapeutics
ANIK stock →Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Healthcare · Drug Manufacturers - Specialty & Generic · 235 employees
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Healthcare · Medical Devices · 162 employees
ANIK vs PROF FAQ
Which is bigger, Anika Therapeutics or Profound Medical?
Anika Therapeutics (ANIK) is larger, with a market capitalization of $261.37M compared with $207.55M for Profound Medical (PROF).
Which stock has performed better over the past year, ANIK or PROF?
ANIK returned +114.85% over the past 12 months, compared with -12.07% for PROF (price return, excluding dividends). Past performance does not predict future results.
Are Anika Therapeutics and Profound Medical in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Anika Therapeutics and Medical Devices for Profound Medical.